AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06210984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg/kg dose of maltodextrin in pill form
Study NCT06558708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR101 Injection
Description: Once daily
Study NCT06558708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR33 Injection
Description: Once daily
Study NCT06558708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Once daily
Study NCT06400147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: This intervention will use an adapted form of strategy training for people with neglect.
Study NCT06400147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: This intervention will use a reflective listening protocol.
Study NCT04887415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory Strength Training (RST) Program
Description: Participants will complete RST exercises 5 days per week by performing 5 sets of 5 repetitions of both expiratory and inspiratory muscle strength training (a total of 50 repetitions per day). Trainer devices will be calibrated to 50% of participants' maximum expiratory pressure (MEP) and maximum inspiratory pressure (MIP) as determined via respiratory assessment prior to and during the RST program.
Study NCT06563115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (PEG)-BHD1028 Single Ascending Dose
Description: 4, 8, 16, 32, and 64 μg/Kg
Study NCT06563115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (PEG)-BHD1028 Multiple Ascending Dose
Description: 8, 16, and 32 μg/Kg
Study NCT06563115 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent
Study NCT05900713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic neuromuscular stabilization training
Description: DNS methods demonstrated efficacy in improving global trunk stabilizing patterns with noted gains in extremity movement and strength
Study NCT05900713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance exercises plus diaphragmatic breathing
Description: The balance exercises is balance exercises while standing and walking The patient assume a semi-Fowler's position and perform diaphragmatic breathing.
Study NCT06558500 — intervention group
Intervention type: PROCEDURE
Intervention: Uterocervical angle
Description: With the patient in the lithotomy position and empty bladder, care was taken to avoid applying pressure to the cervix with the transvaginal probe. The cervix was aligned in the midline, and the endocervical canal was visualized throughout its length.During cervical measurement, care was taken to ensure that the internal os, external os, and entire endocervical canal were visible in the same image. With the endocervical canal, external os, and internal os linearly displayed on the screen, the angle between the endocervical canal, anterior and posterior uterine segment was measured using the ultrasound's angle measurement feature.For the measurement of the uterocervical angle, the first line of the angle was defined along the endocervical canal used for measuring cervical length, and the second line was drawn from the internal os along the anterior uterine segment for a minimum of two centimeters. The angle between these two lines was recorded as the uterocervical angle in the form.
Study NCT06562647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY001
Description: PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages
Study NCT04950738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pess tack acupuncture
Description: Patients enrolled will receive intervention in a form of either press tack acupuncture needles or press tack placebos. Three total intervention sessions will be taken place on day 1,3,5 from patient's enrolment. Needles/placebos skin withdrawal will be done 48 hours after treatment by an acupuncture doctor or by a trained ICU nurne. In cases when a patient will be transferred from the ICU, the 3 study interventions will be continued in the new ward.
Study NCT04950738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pess tack placebo
Description: pess tack stickers without a needle
Study NCT06459973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous (IV) infusion
Description: YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle
Study NCT05495295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PhOx430
Description: The implementation of this cohort (Step 3) was decided by the Protocol Steering Committee (PSC) based on clinical and pharmacokinetic data obtained in Steps 1 and 2. Six patients will be enrolled, who will receive PhOx430 orally thrice a day (tid) at a -6-hour interval over 12 hours for 21 days, and then, starting from day 22, four times a day (qid) at a 4-hour interval over 12 hours, continuously in cycles of 21 days. PhOx430 will be taken in single doses of 1,200 mg to patients weighing ≥ 50 kg and of 600 mg to patients weighing \< 50 kg, with no requirement for a full or empty stomach. The first patient will be observed after treatment start for at least 21 days before enrolling the following two. After the third patient is observed for 21 days after treatment start, 3 additional patients will be enrolled without waiting time between them. If the daily dose tested with the tid schedule is not deemed safe, the flat dose will be tested twice a day (bid) at a 12-hour interval.
Study NCT04786210 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil
Description: Split-scar fractional ablative erbium laser-assisted delivery of 50mg/mL of 5-fluorouracil solution to one half of the scar (4 treatments)
Study NCT04786210 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide
Description: Split-scar fractional ablative erbium laser-assisted delivery of 10 mg/mL of triamcinolone acetonide solution to the other half of the scar (4 treatments)
Study NCT06433115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lean (93%) Grass-Fed Beef
Description: The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
Study NCT06433115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lean (93%) Grain-Fed Beef
Description: The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
Study NCT06433115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-Based Meat
Description: Plant-based meat would be macronutrient matched to the same quantities of meat prescribed for a given energy level.
Study NCT04814823 — intervention group
Intervention type: DEVICE
Intervention: Pulse oximeter
Description: OLV-4202 pulse oximeter (SW version: 01-11)
Study NCT06251687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial Cryobiopsy，TBLC
Description: Transbronchial lung cryobiopsy (TBLC) is a novel technique that has proved its diagnostic value in various diffuse parenchymal lung diseases
Study NCT06251687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial Lung Biopsy，TBLB
Description: Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
Study NCT05712668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative counseling
Description: Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.
Study NCT05712668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative counseling
Description: Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.
Study NCT05712668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asynchronous telemedicine
Description: An asynchronous video will be delivered by Mytonomy. This platform allows investigators to track user analytics relating to the time, frequency, or duration watched by the user.
Study NCT06448377 — intervention group
Intervention type: PROCEDURE
Intervention: Videolaryngoscopy
Description: Situations in which the practitioner performs endotracheal intubation using a videolaryngoscope during airway intervention will be included in this group.
Study NCT06448377 — intervention group
Intervention type: PROCEDURE
Intervention: FOB
Description: Situations in which the practitioner performs endotracheal intubation using a fiberoptic bronchoscope during airway intervention will be included in this group.
Study NCT06448377 — intervention group
Intervention type: PROCEDURE
Intervention: FOB+Aintree
Description: Situations in which the practitioner performs endotracheal intubation using a Fiberoptic intubation via LMA with aintree catheter during airway intervention will be included in this group.
Study NCT06448377 — intervention group
Intervention type: PROCEDURE
Intervention: Classic intubation with laryngoscopy
Description: Situations in which the practitioner performs endotracheal intubation using a macintosh laryngoscope during airway intervention will be included in this group.
Study NCT06448377 — intervention group
Intervention type: PROCEDURE
Intervention: Others
Description: Cases in which intubation cannot be performed, those who are awakened from anesthesia, or those in whom a surgical method is used for airway access will be included in this group.
Study NCT04903860 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total hip replacement with single use ancillary
Description: Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
Study NCT04903860 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total hip replacement with conventional ancillary
Description: Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
Study NCT05752448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POSTCare Survivorship transition process
Description: Survivorship coaching intervention
Study NCT05237388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: One pill daily
Study NCT05237388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Baricitinib placebo pill
Study NCT04636034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Block with Local Anesthetic
Description: Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL
Study NCT04636034 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)
Description: Block performed with bilaterally inserted q-tips with isotone NaCl
Study NCT04636034 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-block with Placebo (Isotone NaCl)
Description: Block performed with bilaterally inserted q-tips with isotone NaCl. The q-tips are inserted a maximum of 3 cm into the nasopharynx thus not reaching the mucus above the ganglion.
Study NCT05007509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine HIPRA 10
Description: One sentinel subject and 4 additional subjects will be assigned to COVID-19 vaccine HIPRA 10 µg
Study NCT05290220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: 1500 mg
Study NCT05146492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI with gadolinium contrast media injection
Study NCT05146492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI with gadolinium contrast media injection
Study NCT05450107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation
Description: Surgical intervention by lag screw or plate fixation
Study NCT05450107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cast immobilisation
Description: Cast immobilsation for a total of 6 weeks with gradual increase in weight bearing after 2 weeks
Study NCT06180980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.
Study NCT05290220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: 300 mg
Study NCT05290220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04
Description: 15mg/kg
Study NCT05007509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine HIPRA 20
Description: One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 20 µg
Study NCT03631628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral Transcutaneous electrical nerve stimulation (Bi-TENS)
Description: The stimulator is a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching, to provide sensory stimulation to both paretic and intact arms. Two pairs of disposable surface electrodes will be applied over the median nerve from the carpal tunnel to the flexor digitorum superficialis and the superficial radial nerve from the extensor pollicis longus to the extensor digitorum communis, with the cathode on the proximal site, and the anode on the distal site.
Study NCT03631628 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bilateral Transcutaneous electrical nerve stimulation (Bi-TENS)
Description: The stimulator is a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching, to provide sensory stimulation to both paretic and intact arms. Two pairs of disposable surface electrodes will be applied over the median nerve from the carpal tunnel to the flexor digitorum superficialis and the superficial radial nerve from the extensor pollicis longus to the extensor digitorum communis, with the cathode on the proximal site, and the anode on the distal site.
Study NCT03631628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Description: A customised angle-adjustable frame with a mirror board will be used. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of mirror, and paretic arm will be placed behind the mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively.~Participants will be encouraged to focus on the image of intact arm when performing upper limb exercises bilaterally.
Study NCT03631628 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: sham-Mirror Therapy (sham-MT)
Description: A customised angle-adjustable frame with a mirror board will be used while the reflecting surface of the mirror was covered with paper. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of covered mirror, and paretic arm will be placed behind the covered mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively.
Study NCT03631628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation Program
Description: Standardized upper limb training
Study NCT03631628 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Rehabilitation Program
Description: Standardized upper limb training
Study NCT06185088 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Coda® Balloon Catheters
Description: A balloon device that will be introduced into participants' intestine over a guide wire to test the radial stretch of the small bowel.
Study NCT06185088 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Double Balloon Endoscope (DBE)
Description: A balloon device that will be introduced retrograde through the ileostomy and the inter-balloon distance will be increased causing stretch on the intestine to test longitudinal stretch. The DBE will only be used if a participant tolerated the Coda® Balloon Catheter intervention.
Study NCT05412576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 2% Injection Solution
Description: Injectable
Study NCT05412576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: Injectable
Study NCT05007509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine HIPRA 40
Description: One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 40 µg
Study NCT05007509 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial COVID-19 vaccine
Description: One subject in cohort 1 and 2 subjects in Cohort 2 and 3 will be assigned to Commercial COVID-19 vaccine
Study NCT06534996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCD-2101
Description: Tradictional Chinese Medicine formula (SCD-2101)
Study NCT06227858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Safr'Inside supplement (Activ'Inside, SAS)
Description: Dietary supplementation will be taken in addition to habitual diet of the patients
Study NCT06227858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plcebo
Description: Placebo capsule (matched to the experimental intervention in terms of colours and taste, without the active compounds saffron)
Study NCT05748990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: 160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
Study NCT05748990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
Study NCT06562478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zazen Meditation
Description: The sessions will last a maximum of 40 minutes in total, comprising 10 minutes of introduction with general practice instructions, followed by 15 minutes of Zazen meditation practice. The final 15 minutes will be allocated for participants to provide feedback on the session.
Study NCT05981040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZYIL1 capsules 25 mg and 50 mg Placebo
Description: ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule
Study NCT05981040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZYIL1 capsules 50 mg and 25 mg Placebo
Description: ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule
Study NCT05981040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg
Description: ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration
Study NCT05981040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo 25 mg and Matching placebo 50 mg
Description: Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
Study NCT06299319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered twice during the trial, in conjunction with supportive therapy.
Study NCT06574620 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic testing
Description: Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.
Study NCT06338787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeSC
Description: Iron/yeast complex
Study NCT06574620 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optional biopsy
Description: Optional collection of tumour tissue and normal tissue prior to the first dose of treatment and/or after the last dose of treatment.
Study NCT05983445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: genakumab
Description: 200mg s.c.
Study NCT05983445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for Diprospan
Description: i.m.
Study NCT05983445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for genakumab
Description: s.c.